Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003090259 | SCV003479229 | uncertain significance | Primary dilated cardiomyopathy | 2022-12-23 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with NEBL-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.009%). This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 541 of the NEBL protein (p.Asp541Tyr). |
Ambry Genetics | RCV004073151 | SCV005025351 | uncertain significance | not specified | 2023-11-12 | criteria provided, single submitter | clinical testing | The p.D541Y variant (also known as c.1621G>T), located in coding exon 16 of the NEBL gene, results from a G to T substitution at nucleotide position 1621. The aspartic acid at codon 541 is replaced by tyrosine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |